Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q2 FY19 results · Jul–Sep 2018
Solara Active Pharma Sciences reported revenue from operations of ₹342.33 crore and net profit of ₹8.55 crore for Q2 FY19 (Jul–Sep 2018), on a consolidated basis.
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 342.33 | — | — | 302.81 | +13.0% |
| Other income | 1.39 | — | — | 0.48 | +187.2% |
| Total income | 343.72 | — | — | 303.30 | +13.3% |
| Profit before tax | 10.18 | — | — | 9.26 | +9.9% |
| Net profit for the period | 8.55 | — | — | 2.58 | +231.5% |
| Attributable to shareholders of the company | 8.53 | — | — | 2.56 | +232.7% |
| EPS, basic (₹) | 3.46 | — | — | 0.23 | not comparable |
| Net margin (%) | 2.5 | — | 0.9 |
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 336.41 | — | — | 302.81 | +11.1% |
| Other income | 0.21 | — | — | 0.43 | −51.2% |
| Total income | 336.62 | — | — | 303.24 | +11.0% |
| Profit before tax | 9.20 | — | — | 9.66 | −4.8% |
| Net profit for the period | 7.57 | — | — | 2.98 | +154.0% |
| EPS, basic (₹) | 1.99 | — | — | 0.39 | not comparable |
| Net margin (%) | 2.3 | — | 1.0 |
Consolidated
- Filed with BSE
- 03 Nov 2018, 15:07 IST
- Board meeting
- 30 Oct 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 03 Nov 2018, 15:07 IST
- Board meeting
- 30 Oct 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE